FDA Approves GENGLYCOS, Ultragenyx's First Gene Therapy

Important Disclosures:

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

A pharma company has grabbed investor attention with its latest FDA approval for a rare disease drug.

Key Takeaways

• The FDA approved GENGLYCOS, Ultragenyx's first gene therapy, for patients 8+ with glycogen storage disease type Ia (GSDIa).
• It's the first FDA-approved treatment designed to target the underlying cause of GSDIa, a rare disorder affecting 1,500 to 2,500 patients in the U.S.
• Approval was based on a Phase 3 study showing a significant drop in cornstarch needs among treated patients over a 48-week span.
• Ultragenyx received a Priority Review Voucher and will provide two years of additional safety and efficacy data from 50 treated patients and 20 control patients through an expanded GSDIa Disease Monitoring Program, with the program following patients for a total of 10 years.
• The therapy will be made at Ultragenyx's Massachusetts facility and given through specialized treatment centers nationwide.

Phase 3 Study Showed Significant Results

Ultragenyx Pharmaceutical Inc. (RARE:NASDAQ) announced on August 19, 2026, that the FDA (U.S. Food and Drug Administration) had granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, marking the company's first gene therapy approval and fifth FDA approval overall. The therapy is approved for adult and pediatric patients eight years and older diagnosed with glycogen storage disease type Ia (GSDIa).

GSDIa is an ultra-rare genetic metabolic disorder caused by a deficiency in the enzyme needed to release glucose from the liver into the bloodstream, which causes it to be associated with potentially life-threatening hypoglycemia. The condition affects an estimated 1,500 to 2,500 patients in the U.S., and 6,000 to 8,000 worldwide. Disease management has traditionally required a demanding, around-the-clock regimen of raw cornstarch intake as an oral glucose replacement, with variable efficacy despite how well the patient adheres to the schedule.

To show just how difficult the disease can be to manage, David and Wendy Feldman, co-founders and board members of The Children's Fund for Glycogen Storage Disease Research, stated: "For families affected by GSDIa, every day revolves around strict schedules, overnight vigilance, and the constant worry that a missed meal or dose of cornstarch could trigger life-threatening hypoglycemia. This approval is an incredibly meaningful milestone for a community that has spent decades hoping, advocating, and helping advance the research for new treatment options that could ease the burdens of this disease." 

GENGLYCOS is the first FDA-approved therapy designed to address the underlying cause of the disease rather than simply manage its symptoms.

"The approval of GENGLYCOS fulfills our commitment to provide the first therapy that directly targets the root cause of GSDIa. The reduced reliance on cornstarch, experienced by patients in our clinical studies, demonstrates this gene therapy's ability to establish the normal breakdown of glycogen to produce glucose during fasting or episodes of metabolic stress. This ability to regulate glucose has alleviated the disease burden and has the potential to mitigate the risk of severe or life-threatening hypoglycemia for these patients," said Eric Crombez, M.D., Chief Medical Officer at Ultragenyx. "As our first gene therapy approval, GENGLYCOS represents an important achievement for our company and the realization of the promise of a powerful new tool to deliver transformative medicines for people living with rare diseases."

The accelerated approval is supported by data from the 48-week, randomized, double-blind, placebo-controlled Phase 3 GlucoGene study, which evaluated 46 participants aged eight and older treated with either DTX401 at a dose of 1.0 x 10^13 GC/kg or a placebo. The study demonstrated a statistically significant reduction in cornstarch requirements among the treated group compared with the placebo (p<0.001). Of the 46 participants, 44 were included in the modified intention-to-treat population used for the Week 48 efficacy analysis, with 20 receiving DTX401 and 24 receiving placebo. At the end of the study, eligible participants crossed over to receive the alternate treatment, with continued follow-up analyses conducted at weeks 96 and 144.

As a condition of accelerated approval, Ultragenyx must generate two years of additional safety and efficacy data from open-label commercial treatment through an expansion of its existing GSDIa Disease Monitoring Program. This post-marketing study will include 50 treated patients and 20 control patients — the latter consisting of individuals who sought commercial treatment but could not receive GENGLYCOS due to the presence of anti-AAV8 antibodies. The program is designed to further evaluate cornstarch burden reduction and fasting tolerance in a real-world setting, and will track both previously treated clinical trial participants and new commercial patients over a total of 10 years. Ultragenyx also received a Priority Review Voucher upon approval.

GENGLYCOS will be manufactured entirely at Ultragenyx's Gene Therapy Manufacturing Facility in Bedford, Massachusetts.

Ultragenyx is a California-based biopharma company focused on developing and bringing to market treatments of serious, rare, and ultra-rare genetic diseases.

Biopharma Funding Fell 20% in 2025

"Day-to-day management of GSDIa requires a relentless regimen of raw cornstarch and strict dietary management that can be extraordinarily demanding for patients and families. Even with meticulous adherence to this regimen, patients must be perfect. Any missed cornstarch puts patients at risk of severe hypoglycemia, seizures, and even death," said David Weinstein, MD, MMSc, and one of the world's leading GSDIa experts.

When rare diseases have so few treatment options, R&D funding becomes crucially important. Biopharma funding fell 20% between 2024 and 2025, according to an IQVIA analysis reported in a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 levels but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

Despite the decline in biopharma spending, demand for medicines remains strong. In February 2026, IQVIA discussed the global pharma market projection for 2026, projecting that global medicine usage will approach four trillion defined daily doses by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

4 Analysts Raise Price Targets

H.C. Wainwright & Co.'s Raghuram Selvaraju, Ph.D., reiterated a "Buy" rating and US$50 price target on August 20, 2026, after Ultragenyx's latest press release. "Commercial availability [of GENGLYCOS] is expected within 30–60 days at a US$2.7M wholesale acquisition cost (WAC), with net pricing near the top of the previously anticipated US$1–2M range and some 2026 revenue anticipated," he wrote.

Recent analyst ratings, according to Marketbeat, include:

• On August 20, 2026, Whitney Ijem of Canaccord Genuity Group reiterated a "Buy" rating and raised the target price from US$81 to US$83.
• On August 20, 2026, Yigal Nochomovitz of Citigroup reiterated a "Buy" rating and raised the price target from US$45 to US$58.
• On August 20, 2026, Benjamin Burnett of Wells Fargo & Company reiterated an "Overweight" rating and raised the price target from US$45 to US$46.
• On August 20, 2026, Kristen Kluska of Cantor Fitzgerald reiterated a "Buy" rating and raised the price target from US$96 to US$103.
• On August 4, 2026, Debjit Chattopadhyay of Guggenheim reiterated a "Buy" rating but lowered the price target from US$43 to US$35.
• On July 7, 2026, Laura Chico of Wedbush reiterated a "Neutral" rating but lowered the price target from US$27 to US$26.

UX111 Approval Decision Expected September

Ultragenyx's August investor presentation lists upcoming catalysts for GTX-102 and UX701. GTX-102, a proposed treatment for Angelman syndrome, is anticipated to complete Phases 2/3 Aurora trial enrollment, as well as receive Phase 3 Aspire data in 2H 2026, with the data expected to be available as early as September. Also in September comes the potential FDA approval of UX111 for the treatment of Sanfillipo syndrome type A.

As for UX701, a proposed treatment for Wilson disease, Stage 1 dose finding data for Cohorts 1-4 is anticipated by Q4 2026.

Currently, Ultragenyx has five FDA-approved medicines — Crysvita, Dojolvi, Mepsevii, Evkeeza, and GENGLYCOS. The company is clinically developing treatments for Angelman Syndrome, GNE Myopathy, Sanfilippo Syndrome, Ornithine Transcarbamylase (OTC), Wilson Disease (WD), and Osteogenesis Imperfecta (OI).

Ownership & Share Information¹

Ultragenyx Pharmaceutical Inc. has a market cap of US$2.59 billion, with 98.59 million shares outstanding. The company's 52-week range is US$18.29-US$39.89. Institutions own 58.75% of shares, while Strategic Investors own 19.75%. Management & Insiders own 3.95% of shares.

Frequently Asked Questions

Q: What is glycogen storage disease type Ia (GSDIa)?
A: GSDIa is a rare inherited metabolic disorder in which the body cannot properly release glucose from stored glycogen, leading to potentially dangerous episodes of low blood sugar.

Q: What is gene therapy?
A: Gene therapy is a treatment approach that modifies, replaces, or adds genetic material to address the underlying cause of a disease rather than only treating its symptoms.

Q: What is an accelerated FDA approval?
A: Accelerated approval is an FDA pathway that allows certain drugs for serious conditions to reach patients sooner based on evidence that they may provide meaningful clinical benefit, with additional studies required after approval.

Q: What is a Priority Review Voucher?
A: A Priority Review Voucher is an FDA incentive awarded to eligible companies for certain treatments, including some therapies for rare pediatric diseases. It can be used to receive priority review for another eligible product or sold or transferred to another company.

Q: Why is cornstarch used to treat GSDIa?
A: Cornstarch provides a source of glucose that can be absorbed gradually and helps people with GSDIa maintain blood sugar levels between meals and during periods of fasting.

Q: What is an AAV gene therapy?
A: An AAV gene therapy uses an adeno-associated virus, or AAV, as a delivery vehicle to transport genetic material into cells. AAV vectors are widely studied for delivering genes in treatments for inherited diseases.